Compare Heron Therapeutics Inc (HRTX) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Vanguard Short Term Corporate Bond ETF trades at $77.34 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 763.1× Heron Therapeutics Inc's market cap, and Vanguard Short Term Corporate Bond ETF is more actively traded (2,892,221 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| HRTX | VCSH | |
|---|---|---|
Market Cap | $68.01M | $51.90B |
Volume | 1,891,941 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $1.49 | $80.20 |
52-Week Low | $0.27 | $77.03 |
Typical Hold Time | 35 Days | 52 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $77.27 with a slight 0.08% daily gain. Technical indicators show a bearish trend from moving averages, though oscillators are neutral. The ETF offers a competitive yield and low expense ratio, but faces headwinds from tight credit spreads and a cautious market outlook. Recent news highlights its role as a stable income alternative to CDs or stable value funds, with institutional activity showing mixed positioning.
The outlook for VCSH is neutral with limited upside due to unattractive entry points and constrained credit spreads. Its short duration minimizes interest rate risk, but yield advantages over peers may narrow. Key risks include corporate credit deterioration and Fed policy shifts. Investors seeking short-term, high-quality bond exposure may find value, but current levels offer modest total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
